New license agreement signed with Sitryx

06th July 2021

Sitryx, a biopharmaceutical company focused on immunometabolism, has entered into a license agreement with Cancer Research UK to develop IP from the Beatson Institute's Drug Discovery Unit relating to small molecule inhibitors of a target kinase, which plays a critical role in a metabolic pathway of emerging importance in immune cells and inflammatory processes:


Research Mahnoor 290x200

Read more about the Research Groups working at the Beatson Institute.



Seminars 2021

Find out more about our seminars including our Distinguished Seminar Programme.